SunWay Biotech Co., LTD. (1271) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of SunWay Biotech Co., LTD. stock TWD 52.40, price TWD 55.90, that is 6.3% below the price, quality 43 out of 100. Rating: fairly valued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.
How to read this chart
60‑month range 41.50 TWD – 133.54 TWD · fair‑value band 35.52 TWD – 82.16 TWD · the 55.90 TWD price screens above the 52.40 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.
Follow SunWay Biotech Co. in your weekly email
Every Wednesday you see whether SunWay Biotech Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
SunWay Biotech Co., LTD. focuses on professional research and development, and technical material manufacturing and processing business.
Show moreShow less
The company offers red yeast rice and lactic acid bacteria products, as well as other health supplements; and wholesale and manufacturing of pharmaceutical products.
The company also researches, designs, and manufactures Monascus purpureus NTU 568; Lactobacillus paracasei subsp. paracasei NTU 101; and related products. The company was founded in 2007 and is based in Taipei, Taiwan.
Stock analysis
SunWay Biotech Co., LTD. (1271) currently trades at 55.90 TWD, while our model-based Fair Value estimate is 52.40 TWD, so the stock looks roughly fairly valued today (gap 6.7%).
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 60.51 TWD per share, and 2 of the 26 models we run sit above the 55.90 TWD price.
Bear case: the Dividend Discount group reads lowest at 11.02 TWD, and 24 of the 26 models stay below the price. Data coverage for this calculation is high.
Scenario range: 35.52 TWD (bear) to 82.16 TWD (bull), the price of 55.90 TWD sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 43/100 (below-average quality), in the Consumer Defensive sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
SunWay Biotech Co., LTD. reported revenue of 993M TWD in FY2025 versus 380M TWD in FY2021, a compound +27.1%/yr. Reported net income was 102M TWD in FY2025, compounding −11.9%/yr from FY2021.
Key figures
Market cap 4.3B TWD (≈ $131M) Micro · P/E ratio 25.5 · P/S ratio 2.80 · EPS (TTM) 2.19 TWD · Dividend yield 1.8% · Net margin 8.9% · Return on equity 3.7% · Return on assets (EBIT) 8.7% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 37 out of 100 (low confidence).
What moves the price
The share trades about 21% below its 52-week high and 9% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Consumer Defensive peers we cover trades at −1% fair-value upside, at −6%, 1271 screens richer than that median.
Fair Value models
Bear35.52 TWDFair Value 52.40 TWDBull82.16 TWD
Price 55.90 TWD · Downside -6.3%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (1.02 TWD per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.90/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+2.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+32.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+25.9%
Start year 2020 (pandemic). Over 10 years: +37.7% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+38.1%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in TWD ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in TWD: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−13.8%
Earnings growth per share plus dividend.
Earnings per share, growth per year−15.6%
Dividend (yield on the price)1.8%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.40% → 11%
Growth Forecast
Price in line with expectations
The price assumes about as much growth as the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+26.9%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Taiwan: IMF forecast 1.6% a year to 2030, 1.5% from 2016 to 2025) that is about +25.0% a year for the price.
Compare SunWay Biotech Co., LTD. with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Packaged Foods · 624 stocks
Beats the industry median on 3/14 measures
Overall it trails its industry peers.
Valuation
Quality Score43 · Bottom 25%
Fair Value upside−6.3% · Below median
Profitability
Return on equity (12 months)3.7% · Below median
Return on assets2.3% · Below median
Net margin (12 months)8.9% · Top 25%
Operating margin (12 months)5.0% · Below median
Growth and dividend
Revenue growth (quarter YoY)116.7% · Top 25%
Dividend yield (12 months)1.8% · Below median
Balance sheet
Debt / equity0.13× · Above median
Valuation Multiplesvs Packaged Foods median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is SunWay Biotech Co., LTD. (1271) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of 52.40 TWD versus a price of 55.90 TWD, about 6% lower (fairly valued).
What is the fair value of 1271?
Our model-based fair value for SunWay Biotech Co., LTD. is 52.40 TWD (as of Nov 8, 2026), built from audited fundamentals. The current price: 55.90 TWD.
What is the quality score of 1271?
SunWay Biotech Co., LTD. has a Quality Score of 43/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for SunWay Biotech Co., LTD. (1271)?
Our model-based price target is the fair value of 52.40 TWD (as of Nov 8, 2026) from 26 valuation models. Cautious scenario 35.52 TWD, optimistic scenario 82.16 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the SunWay Biotech Co., LTD. stock forecast for 2026?
Our models put fair value at 52.40 TWD, about 6% lower versus a price of 55.90 TWD (fairly valued). Cautious scenario 35.52 TWD, optimistic scenario 82.16 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of SunWay Biotech Co., LTD. (1271)?
SunWay Biotech Co., LTD. reported trailing-twelve-month revenue of about 1.5B TWD (latest available figure, as of Nov 8, 2026).
Does SunWay Biotech Co., LTD. pay a dividend?
SunWay Biotech Co., LTD. currently shows a dividend yield of 1.79% relative to its recent price (as of Nov 8, 2026).
How much is the dividend of SunWay Biotech Co., LTD. (1271) and when is the ex-dividend date?
SunWay Biotech Co., LTD. pays a dividend of 1.00 TWD per share a year, a dividend yield of 1.8%. The last ex-dividend date was Jul 30, 2026. A dividend has been paid every year since at least 2021. The payout ratio is 45.7% of earnings. Free cash flow covers the dividend 1.55 times. Our assessment: Well covered. A low payout and the dividend is fully funded by free cash flow, a comfortable, sustainable dividend.
What growth is priced into SunWay Biotech Co., LTD. (1271)?
For today's price to be fair in a discounted-cash-flow model, SunWay Biotech Co., LTD. would have to grow free cash flow by +26.9 % per year for five years (discount rate 13.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +25.9 % per year. As of Nov 8, 2026.
What discount rate (WACC) does the fair value of 1271 use?
Our models discount SunWay Biotech Co., LTD. at 13.3 %: a base by market capitalisation (micro), country premium for Taiwan. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For SunWay Biotech Co., LTD. that is +26.9 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (13.3 %) and the same formula as our fair value.
How much growth has SunWay Biotech Co., LTD. (1271) delivered so far?
Over the past 5 years revenue at SunWay Biotech Co., LTD. grew +25.9 % a year. The price currently implies free-cash-flow growth of +26.9 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of SunWay Biotech Co., LTD. (1271) growing?
The median revenue growth in the sector is +2.0 % a year. That is the yardstick for the growth priced into SunWay Biotech Co., LTD. (+26.9 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of SunWay Biotech Co., LTD. (1271)?
The free-cash-flow yield on the price is 3.54 %: that much free cash flow SunWay Biotech Co., LTD. produces per unit of market value. When it exceeds the discount rate of our models (13.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of SunWay Biotech Co., LTD. (1271)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For SunWay Biotech Co., LTD. it is 52.40 TWD per share (as of Nov 8, 2026), against a price of 55.90 TWD. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is SunWay Biotech Co., LTD. stock overvalued or undervalued in 2026?
As of Nov 8, 2026, 1271 trades above its calculated fair value: price 55.90 TWD, fair value 52.40 TWD, a gap of about −6% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 1271?
No. The price is what the market pays today (55.90 TWD); the fair value is what the company's own numbers justify (52.40 TWD). For SunWay Biotech Co., LTD. the two are 3.50 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is SunWay Biotech Co., LTD. worth?
The market values SunWay Biotech Co., LTD. at about 4.3B TWD (market capitalisation, as of Nov 8, 2026). Per share that is 55.90 TWD; our models calculate a fair value of 52.40 TWD per share.
What do the bullish and bearish scenarios say about 1271?
Our models span a range for SunWay Biotech Co., LTD.: cautious scenario 35.52 TWD, base 52.40 TWD, optimistic 82.16 TWD per share (as of Nov 8, 2026, price 55.90 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 1271?
SunWay Biotech Co., LTD. trades at a price-to-earnings ratio of 25.5 (as of Nov 8, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 52.40 TWD is built from several models across several years. Other multiples: P/B 1.3, P/S 2.8, EV/EBITDA 28.4.
How solid is the balance sheet of SunWay Biotech Co., LTD. (1271)?
Balance-sheet figures for SunWay Biotech Co., LTD. (as of Nov 8, 2026): return on equity 3.7%, debt of 0.13 per unit of equity. They feed the Quality Score of 43/100, which measures business quality independently of the share price.
How far is 1271 from its 52-week high?
SunWay Biotech Co., LTD. trades at 55.90 TWD, about 21% below its 52-week high of 70.60 TWD and 9% above the low of 51.50 TWD (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 52.40 TWD is for.
Which stocks are comparable to SunWay Biotech Co., LTD.?
From the same area (Consumer Defensive) we also value Nestlé S.A, Danone S.A, Foshan Haitian Flavouring and Food Company, The Kraft Heinz Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is SunWay Biotech Co., LTD. stock attractive at the current price?
The data as of Nov 8, 2026: price 55.90 TWD, calculated fair value 52.40 TWD (−6%), Quality Score 43/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 1271 calculated?
We run SunWay Biotech Co., LTD. through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 52.40 TWD builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. SunWay Biotech Co., LTD. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of SunWay Biotech Co., LTD. (1271)?
The closing price on Nov 6, 2026 was 55.90 TWD. Our model-based fair value is 52.40 TWD, about 6% lower (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with SunWay Biotech Co., LTD. right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range (35.52 TWD to 82.16 TWD) leaves room in how you read the outcome.
Key figures of SunWay Biotech Co., LTD.
How large is the market capitalisation of SunWay Biotech Co., LTD. (1271)?
The market capitalisation of SunWay Biotech Co., LTD. is 4.3B TWD (≈ $131M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of SunWay Biotech Co., LTD. (1271)?
The price-to-sales ratio of SunWay Biotech Co., LTD. is 2.80 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of SunWay Biotech Co., LTD. (1271)?
Earnings per share at SunWay Biotech Co., LTD. are 2.19 TWD (price ÷ EPS = P/E 25.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of SunWay Biotech Co., LTD. (1271)?
The dividend yield of SunWay Biotech Co., LTD. is 1.8% (payout 45.7%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of SunWay Biotech Co., LTD. (1271)?
The net margin of SunWay Biotech Co., LTD. is 8.9% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of SunWay Biotech Co., LTD. (1271)?
The return on equity (ROE) of SunWay Biotech Co., LTD. is 3.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of SunWay Biotech Co., LTD. (1271)?
On an EBIT basis the return on assets of SunWay Biotech Co., LTD. is 8.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of SunWay Biotech Co., LTD. (1271)?
The operating margin of SunWay Biotech Co., LTD. is 5.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at SunWay Biotech Co., LTD. (1271)?
Revenue at SunWay Biotech Co., LTD. is growing +117% versus a year earlier (3y avg +32.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at SunWay Biotech Co., LTD. (1271)?
Earnings per share at SunWay Biotech Co., LTD. are growing +69.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does SunWay Biotech Co., LTD. (1271) carry?
The net debt of SunWay Biotech Co., LTD. is 358M TWD (fiscal year 2025, ≈ 3.0 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch SunWay Biotech Co., LTD. in the live analysis
One click puts SunWay Biotech Co., LTD. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 8, 2026